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Abstract
Background: Adherence to anti-osteoporosis treatments is poor, exposing treated women to increased fracture
risk. Determinants of poor adherence are poorly understood. The study aims to determine physician- and patient-
rated treatment compliance with osteoporosis treatments and to evaluate factors influencing compliance.
Methods: This was an observational, cross-sectional pharmacoepidemiological study with a randomly-selected
sample of 420 GPs, 154 rheumatologists and 110 gynaecologists practicing in France. Investigators included post-
menopausal women with a diagnosis of osteoporosis and a treatment initiated in the previous six months.
Investigators completed a questionnaire on clinical features, treatments and medical history, and on patient
compliance. Patients completed a questionnaire on sociodemographic features, lifestyle, attitudes and knowledge
about osteoporosis, treatment compliance, treatment satisfaction and quality of life. Treatment compliance was
evaluated with the Morisky Medication-taking Adherence Scale. Variables collected in the questionnaires were
evaluated for association with compliance using multivariate logistic regression analysis.
Results: 785 women were evaluated. Physicians considered 95.4% of the sample to be compliant, but only 65.5%
of women considered themselves compliant. The correlation between patient and physician perceptions of
compliance was low (: 0.11 [95% CI: 0.06 to 0.16]). Patient-rated compliance was highest for monthly
bisphosphonates (79.7%) and lowest for hormone substitution therapy (50.0%). Six variables were associated with
compliance: treatment administration frequency, perceptions of long-term treatment acceptability, perceptions of
health consequences of osteoporosis, perceptions of knowledge about osteoporosis, exercise and mental quality of
life.
Conclusion: Compliance to anti-osteoporosis treatments is poor. Reduction of dosing regimen frequency and
patient education may be useful ways of improving compliance.
Background
Anti-osteoporosis treatmentss u c ha sb i s p h o s p h o n a t e s ,
selective oestrogen receptor modulators (SERMs) and
strontium ranelate have been demonstrated to reduce
significantly the risk of osteoporotic fracture in women
with post-menopausal osteoporosis [1]. Nonetheless, the
effectiveness of these treatments in routine clinical prac-
tice may be compromised by poor treatment adherence.
Indeed, a number of studies have reported low
compliance or persistence rates, notably with bispho-
sphonates [2], and others have demonstrated that poor
adherence compromises control of fracture risk [3,4].
A number of strategies have been proposed for
improving adherence to treatment in post-menopausal
osteoporosis, including reduction of dosing frequency,
patient education programmes and bone mineral densi-
tometry or other surrogate markers to help patients fol-
low treatment-related changes in bone mass [5]. In
order to evaluate the utility of such measures, it is
important to acquire data on how patients view their
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variables that are associated with adherence.
We have recently performed a large, observational,
pharmacoepidemiological study of osteoporosis and its
treatment in primary and secondary care in France
(POSTEPI study). The primary objective of the study
was to describe the characteristics of women receiving
treatment for osteoporosis diagnosed in the previous six
months. Secondary objectives were to identify variables
potentially associated with different treatment regimens,
to assess impact on quality of life, and to evaluate
patient adherence to, and satisfaction with, their anti-
osteoporosis treatment. The treatment data will be pre-
sented elsewhere. This article reports the data on adher-
ence and patient satisfaction.
Methods
This was an observational, cross-sectional pharmacoepi-
demiological study performed in France between
November 2007 and March 2008.
Participating physicians
General practitioners (GPs), gynaecologists and rheuma-
tologists participated in the study. These were selected
at random from a national physician list (CEGEDIM
database) using a sampling method stratified by region.
The planned number of participating physician was 650.
Subjects
Participants included all women in whom bone densito-
metry had been performed or who had experienced a
fracture not related to trauma or cancer in the previous
six months in a patient registry. Of these, the first three
post-menopausal women in whom a diagnosis of osteo-
porosis had been made on the basis of low bone mass
density or fracture occurrence in the previous six
months, and for whom osteoporosis treatment was
initiated, constituted, the questionnaire population.
Exclusion criteria included participation in studies likely
to have influenced treatment and illiteracy.
Data collection
Participating physicians provided general professional
information and specific information on osteoporosis
management. For each patient included in the registry,
the physician noted the age of the patient, the age at
menopause, the age at which osteoporosis was diag-
nosed, information on densitometry, fractures, fracture
risk factors and any current or planned osteoporosis
treatments. For the questionnaire population, each parti-
cipating physician completed a medical questionnaire.
This included items on height, weight, exercise, fracture
history, osteoporosis management, comorbidities, and
comedication. In addition, the physician provided
patients with a questionnaire to complete. This collected
data on sociodemographic features, lifestyle, attitudes
and knowledge concerning osteoporosis and its treat-
ment, treatment compliance, treatment satisfaction and
quality of life. Information on compliance was collected
both from physicians and from patients. Physicians were
asked whether they considered their patients to be fully
compliant. Treatment compliance from the patient
point of view was evaluated with the French version of
Morisky Medication-taking Adherence Scale (MMAS)
(Additional file 1) [6] and quality of life with the SF-12
health profile measure, both completed by the patient.
Both were used in their validated French translations.
Treatment satisfaction was assessed by asking the
patient if she was satisfied with her osteoporosis treat-
ment. Five response modalities were possible. For the
purposes of the analysis, replies were grouped into three
classes (very/rather unsatisfied, neither satisfied nor dis-
satisfied, or very/quite satisfied). Patients were also
asked whether they considered their treatment regimen
to be adapted to their lifestyle and whether they consid-
ered the frequency of administration of their treatment
regimen to be easy to maintain over the long term. The
completed questionnaire was returned directly to the
data management centre.
The MMAS contains four items to which a yes or no
reply is given (Additional file 2). These questions are
‘Do you ever forget to take your [osteoporosis] medicine?’,
‘Do you ever have problems remembering to take your
[osteoporosis] medication?’, ‘When you feel better, do you
sometimes stop taking your [osteoporosis] medicine?’ and
‘Sometimes, if you feel worse when you take your [osteo-
porosis] medicine, do you stop taking it?’. Each ‘no’ reply
is scored as one and each ‘yes’ reply is scored as zero,
allowing a total possible score ranging from zero (worst
compliance) to four (full compliance). A patient was
considered non-compliant to treatment if her score on
the MMAS was less than four.
Statistical analysis
The present analysis was restricted to those patients in
whom a treatment had been initiated during the pre-
vious six months. Statistical comparisons were per-
formed using the c
2 test or Fisher’se x a c tt e s tf o r
categorical variables and analysis of variance or the
Wilcoxon test for quantitative variables. All tests were
two-tailed. A probability threshold of 0.05 was taken as
statistically significant. Variables associated with compli-
ance were evaluated by multivariate logistic regression
analysis using a rising stepwise procedure with a cut-off
probability threshold of 0.1 at each step. The variables
entered into this analysis corresponded to all those col-
lected in the case report form whose frequencies dif-
fered between compliant and non-compliant patients at
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multivariate model was generated in which only vari-
ables retained in the stepwise model were entered in
order to generate odds ratios for the association with
compliance. Data were analysed using SAS® software,
Version 8.2 (SAS, Cary, USA) on Windows.
Ethics
The survey protocol was submitted for evaluation to the
CCTIRS (National Ethics Advisory Board). They consid-
ered that participation of patients in the study would
not affect their medical care, and therefore that it was
not necessary to obtain formal Ethics Committee
approval nor to collect signed informed consent from
each patient. The only requirement stipulated was that
formal information on the goals and methods of the
study be provided for each patient. Procedures for data
collection and management were approved by the Con-
seil National de l’Informatique et des Libertés (CNIL),
which ensures that all medical information is kept confi-
dential and anonymous.
Results
Participating physicians
Overall, 684 physicians included patients in the registry,
namely 420 GPs, 154 rheumatologists and 110
gynaecologists.
Subjects
The first three registry patients included per investigator
(n = 1,306) were entered into the questionnaire study
a n dp r o p o s e da na u t o q u e s t i o n n a i r e .C o m p l e t e da u t o -
questionnaires were received from 1,217 women
(93.2%), who constituted the autoquestionnaire popula-
tion. The analysis reported here is restricted to the 785
women who had already been prescribed a treatment at
the time of the consultation. For the remaining 521
women, treatment was initiated during the consultation
and compliance thus could not be assessed.
Patient characteristics and treatment are presented in
Table 1.
Compliance
The physicians considered their patients to be fully
compliant in almost all cases (Table 2). From the
patients’ perspective, 65.5% of women considered them-
selves to be fully compliant (MMAS score = 4), and the
correlation between patient and physician perceptions of
compliance was very poor (p = <0.001; MacNemar test;
 coefficient = 0.11 [95% CI: 0.06 to 0.16]). Nonetheless,
patients who rated themselves as fully compliant were
more likely to be considered compliant by their physi-
cians and vice versa (p < 0.01: Cochran-Mantel Haenszel
test; Table 2). Patient-rated compliance differed between
the different treatments (p <0.001; Figure 1), being high-
est for monthly bisphosphonates (79.7%) and lowest for
hormone substitution therapy (50.0%).
Satisfaction
Data on treatment satisfaction is presented in Table 3.
The rate of treatment satisfaction varied with the fre-
quency of administration (p = 0.001; c
2 test), being
highest with monthly treatments. Satisfaction did not
however, differ between the different classes of medica-
tion (p = 0.05; c
2 test; data not shown).
Variables associated with compliance
In a first step, all variables collected during the course of
the study were evaluated for their potential association
with patient-reported compliance (MMAS score = 4
compared to score < 4) using univariate analysis. Vari-
ables related to attitudes to disease and treatment identi-
fied on the autoquestionnaire are listed in Table 4. After
a stepwise multivariate regression analysis, six variables
were retained and corresponding odds ratios generated
(Table 5), namely frequency of treatment administration,
whether the patient considered the frequency of treat-
ment administration to be adapted to long-term treat-
ment, whether she considered that her osteoporosis
could have consequences for her health, whether she
considered herself well-informed about osteoporosis,
whether she walked for at least twenty minutes each day
and the mental component score of the SF-12.
Table 1 Characteristics of women treated for osteoporosis at the time of the consultation (questionnaire population;
N = 785).
Patient characteristics Treatments
Age (years) 66.30 ± 9.07 Daily bisphosphonates 17 (2.2%)
Age at menopause (years) 49.75 ± 3.97 Weekly bisphosphonates 305 (40.6%)
Time since menopause (years) 16.49 ± 9.38 Monthly bisphosphonates 202 (26.9%)
Densitometry in the last six months 667 (85.3%) SERMs 76 (10.1%)
Osteoporotic fractures 389 (51.7%) Strontium ranelate 119 (15.8%)
At least one risk factor 618 (78.7%) Others 26 (3.5%)
Data are presented as mean ± SD for quantitative variables and as numbers of women (%) for categorical variables. Data were missing for up to six patientsf o r
certain variables. SERM: selective oestrogen receptor modulators. ‘Others’ include parathyroid hormone analogues and hormone substitution therapy.
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In this study, we observed a large discrepancy between
treatment compliance as evaluated by the investigator
and as considered by the patient. Although the physi-
cians thought that compliance was adequate for over
95% of women, only two-thirds of the patients rated
themselves as fully compliant.
Compliance rates (as defined by the patient) differed
between medication groups, being highest for bispho-
sphonates and lowest for HRT and strontium ranelate.
Given the very small number of women taking HRT,
t h ep r e c i s i o no ft h ec o m p l i a n c er a t ef o rt h i st r e a t m e n t
should be regarded as limited. Among the bisphospho-
nates, significant differences in compliance were
Table 2 Compliance with treatment as rated by the physician and patient.
TOTAL
Physician-rated compliance
Patients considered compliant 748 (95.4%)
Patient-rated compliance
MMAS score (mean ± SD) 3.34 ± 1.07
Compliant patients (Morisky score = 4) 483 (65.5%)
Concordance
Patients considered compliant by both physician and patient 476 (64.6%)
Patients considered non-compliant by both physician and patient 26 (3.5%)
Kappa concordance coefficient 0.11 [95% CI: 0.06 to 0.16]
Significant differences in reply distributions were not observed between the three physician groups. Data for physician-reported compliance concern the
questionnaire population (N = 785; missing data: N = 1) and for patient-rated compliance and concordance the autoquestionnaire population (N = 751; missing
data: N = 13). MMAS: Morisky Medication-taking Adherence Scale.
Figure 1 Proportion of patients rating themselves as fully compliant (MMAS scale score = 4) according to medication class.D a t a
presented with 95% Confidence Interval limits (95% C.I.). BP: bisphosphonate; HRT: hormone replacement therapy; SERM: selective oestrogen
receptor modulator.
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highest for monthly preparations and lowest for daily
regimens. Indeed, in the multivariate regression analysis,
treatment administration frequency was the variable
with the strongest association with compliance, with an
increased probability of being compliant to a monthly
treatment over twofold higher than for a daily treat-
ment. Other variables associated with improved compli-
ance were the patient’s view of the consequences of
osteoporosis, knowledge about osteoporosis, walking
over twenty minutes a day, and a higher mental compo-
nent quality of life score. Somewhat surprisingly, pre-
vious fracture experience did not influence compliance.
It will be important to validate whether these determi-
nants of compliance can be reproduced in prospective
longitudinal studies of the treatment of osteoporosis.
Around sixty percent of women reported being quite
or very satisfied with their treatment, and a similar pro-
portion considered following their treatment to be a
priority for their health. Treatment satisfaction was also
higher in women receiving a monthly treatment than a
weekly treatment, and in those receiving a weekly treat-
ment compared to a daily one.
The study has a number of strengths and limitations.
The strengths include the relatively large sample size, the
sampling method, which should ensure representativity
Table 3 Treatment satisfaction as a function of frequency of administration (all treatments combined).
Daily Weekly Monthly TOTAL
Patient satisfaction regarding osteoporosis treatment p ≤ 0.001
Very unsatisfied or rather unsatisfied 4 (2%) 5 (8%) 1 (4%) 10 (13.8%)
Neither satisfied nor dissatisfied 081 (38.9%) 119 (41.2%) 069 (30.5%) 269 (37.2%)
Quite satisfied or very satisfied 123 (59.1%) 165 (57.1%) 156 (69.0%) 444 (61.4%)
Treatment regimen considered adapted to lifestyle
188 (89.5%) 279 (97.2%) 226 (99.6%) p ≤ 0.001
Frequency of treatment administration considered easy to maintain over the long-term
170 (81.3%) 262 (91.3%) 218 (96.5%) p ≤ 0.001
Data were missing for up to three patients for certain variables.
Table 4 Autoquestionnaire variables independently associated with compliance identified by univariate regression
analysis.
Variable Response modality Non-compliant
N = 255
Compliant
N = 483
p
Osteoporosis considered as an illness Yes 172 (67.1%) 378 (79.1%) 0.001
Consequences of osteoporosis according to the patient Serious
Quite serious
Not serious
62 (24.3%)
150 (58.8%)
43 (16.9%)
198 (41.3%)
244 (50.8%)
81 (11.0%)
≤0.001
Known osteoporotic risk factors before diagnosis Yes 43 (16.9%) 143 (29.6%) ≤0.001
Well Informed on osteoporosis since diagnosis Strongly agree
Agree
Disagree
Strongly disagree
41 (16.1%)
46 (18.1%)
164 (64.6%)
3 (1.2%)
170 (35.2%)
37 (7.7%)
274 (56.7%)
2 (0.4%)
≤0.001
Osteoporosis treatment considered as a priority Strongly agree
Agree
Disagree
Strongly disagree
69 (27.1%)
37 (14.5%)
144 (56.5%)
5 (2.0%)
228 (47.3%)
35 (7.3%)
216 (44.8%)
3 (0.6%)
≤0.001
Patients perspective: possible Less than 3 months
3 months to 1 year
1 to 3 years
More than 3 years
1 (0.4%)
9 (3.7%)
68 (27.9%)
166 (68.0%)
0 (0.0%)
4 (0.8%)
96 (20.1%)
377 (79.0%)
≤0.001
Walking over 20 min per day Yes 128 (50.2%) 312 (65.0%) ≤0.001
Physical component score of SF12 (PCS) Score unit 44.50 ± 7.66 45.85 ± 8.06 0.041
Mental component score of SF12 (MCS) Score unit 43.16 ± 9.78 46.03 ± 10.06 ≤0.001
Satisfied by osteoporosis treatment Very/rather unsatisfied
Neither satisfied nor unsatisfied
Very/quite satisfied
6 (2.4%)
130 (51.2%)
1180 (46.4%)
4 (0.8%)
141 (29.6%)
331 (69.5%)
≤0.001
Treatment regimen adapted to your lifestyle Yes 235 (92.5%) 468 (97.5%) 0.003
Treatment regimen difficult to follow for a long-time No 201 (79.8%) 461 (96.0%) ≤0.001
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secondary care in France, the relatively high response
rate, and the collection of data directly from the patients.
The principal limitation relates to the choice of the
instrument for determining compliance to treatment.
T h eu s eo fap a t i e n t - c o m p l e t e dq u e s t i o n n a i r ei sa p p r o -
priate for a naturalistic study such as this, but relies on
the accuracy of patient self-report, which cannot be inde-
pendently controlled. This potential source of bias is
compounded by the fact that the data were collected ret-
rospectively. The use of a more objective measure, such
as pill count, may have provided more accurate data but
could have introduced a significant uncontrolled bias in
that implementation of the measure may have modified
the compliance behaviour that it was set up to report.
The MMAS [6] was originally developed to assess com-
pliance to medication use in patients with essential
hypertension, but has subsequently been used success-
fully in other fields of medicine in which adherence is a
particular issue, including asthma, HIV, diabetes mellitus
and bipolar disorder. In addition, the interpretation of
the magnitude of difference between physician- and
patient-rated compliance should be tempered by the fact
that the instruments used to collect this information
were different. In addition, it is clear that other potential
determinants of compliance may exist, on which data
were not collected in this study. These include patient
preference for different treatments and participation in
the choice of treatment. Finally, the fact that participation
in the study by physicians was voluntary may introduce
bias if these are not representative of the French physi-
cian population, for example with respect to providing
information on treatments to their patients.
Poor discernment by physicians of their patients’ sub-
jective view of their medical condition has been
demonstrated previously for health outcomes, such as
health-related quality of life [7], treatment tolerability
[8] or functional disability [9]. With regard to adher-
ence, differences in physician- and patient-perceived
compliance such as those described here have been
reported previously in many other areas of medicine,
notably in psychiatry [10,11]. Similarly, a previous study
has shown that physicians did not correctly estimate
patient-reported compliance to HIV therapy in 35% of
patients [12].
The differences observed in compliance between treat-
ment classes is also consistent with a number of pre-
vious studies [13-15], as is the association between
compliance and poor quality of life [16]. A relationship
between frequency of treatment administration and
treatment preference has previously been reported in
the two BALTO studies, which used a randomised,
cross-over design to compare a monthly and a weekly
formulation of bisphosphonates [17].
A recent study reported that many individuals who
suffered from a fragility fracture did not associate their
fracture with osteoporosis and speculated that there
may be a relationship between risk perception and
adherence to therapy [18]. Our findings showed that
patients in the non-compliant group were characterised
by less appropriate perceptions of disease status and less
knowledge about risk factors and consequences of
osteoporosis. Similarly, not considering osteoporosis to
be a serious disease was another factor associated with
non-compliance.
The findings of this study have several implications.
Firstly, they emphasise the importance of collecting data
on adherence directly from the patient, rather than from
the physician. Secondly, our results showed that patients
who considered themselves poorly informed about their
Table 5 Odds ratios variables independently associated with compliance identified by multivariate regression analysis
(odds ratios presented with their 95% confidence intervals).
Effect Response Odds Ratio p
Frequency of administration adapted to long-term treatment No 1.00
Yes 4.227 [2.272; 7.863] < 0.0001
Frequency of treatment administration Daily 1.00 .
Weekly 1.273 [0.836; 1.938] 0.2607
Monthly 2.232 [1.367; 3.643] 0.0013
Consequences of osteoporosis according to the patient Serious 1.00
Quite serious 0.617 [0.407; 0.937] 0.0234
Not serious 0.466 [0.250; 0.868] 0.0161
Well Informed on osteoporosis since diagnosis Strongly agree 1.00 .
Weakly agree 0.564 [0.358; 0.889] 0.0006
Disagree 0.322 [0.169; 0.616] 0.0136
Walking over 20 minutes a day No 1.00
Yes 1.496 [1.031; 2.171] 0.0341
Mental component score of SF12 One point increment 1.021 [1.002; 1.040] 0.0328
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study, osteoporotic women claimed that their healthcare
providers did not always give them enough information
about medications or gave them information in a format
that was difficult to understand. In this study, the
absence of a satisfactory exchange of information
between physicians and patients was identified as a
major determinant of adherence [19]. One of the most
effective approaches for improving medication adher-
ence may thus be to encourage more open, co-operative
relationships that lead to concordance between the phy-
sician and patient [20].
Women who walked over twenty minutes a day also
reported better compliance than those who did not, per-
haps because they attach more importance to keeping
well and taking control of their health in general. The
behaviour of such patients who take an active role in
managing lifestyle patterns that have an impact on their
disease has previously been described in the field of type
2 diabetes [21], where these ‘Disease Managers’ tend to
show high treatment adherence rates.
The observed association between compliance and
patient beliefs and attitudes with respect to osteoporosis
reinforces the interest of patient education measures fol-
lowing diagnosis for all women with post-menopausal
osteoporosis. Understanding patients’ health beliefs bet-
ter and re-orientating these when they are inaccurate
m a yt h u sb eau s e f u lk e yt oi m p r o v ec o m p l i a n c e[ 2 2 ] .
Medication beliefs have indeed been shown elsewhere to
be more powerful predictors of reported adherence than
clinical and socio-demographic factors [23]. The authors
of the latter study proposed that many patients engaged
in an implicit cost-benefit analysis in which beliefs
about the necessity of their medication are weighed
against concerns about the potential adverse effects of
taking it, and that these beliefs influenced medication
adherence.
Methods to assess adherence are multiple and very
different from each other and that, even in the single
field. In the osteoporosis literature[24], reported meth-
ods based on the care provider (eg, pill count, physical
examination for frequent clinical adverse effects),
patients (patients’ self-report [eg, written or electronic
diary], elicited report [eg, global or specific questioning],
or other methods), use of devices (eg, pill count by elec-
tronic monitoring), biologic elements (eg, serum levels,
urine levels, measurement of expected biologic effects),
or other methods. Pharmacy data give one measure of
adherence whose main advantages are sample size and
being almost exempt from selection bias. However,
principal well-known limit of pharmacy database is
absence of information about patients’ behaviors with
tablets at their home (omission, drug holiday etc.). In
this study, MMAS questionnaire took into account
those behavioural aspects as an informative and comple-
mentary measure. Thus, our results showing better
compliance with monthly regimen are consistent with
recent ones on French prescription database [25].
Conclusions
The POSTEPI study confirmed that compliance to anti-
osteoporosis treatments as considered by the patient is
poor, but identified reduction of the dosing regimen fre-
quency and patient education measures as potentially
useful ways of improving compliance.
Additional material
Additional file 1: French version of Morisky Medication-taking
Adherence Scale (MMAS) - 4 items. Linguistic validation by Mapi
Research Institute consisted in forward, backward translation, clinician’s
review and patients’ cognitive debriefing.
Additional file 2: US original version of Morisky Medication-taking
Adherence Scale (MMAS) - 4 items.
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